Gene therapy deaths push back Astellas-Audentes' approval by at least two years
The three deaths in an Astellas gene therapy trial last year will push back the experimental therapy’s approval by “more than two years” as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
